Categories Uncategorized

Why Psychedelics and Meditation Go Well Together

Meditation can be described as a way of changing your state of awareness without using any substances. This practice is not new, especially in the Buddhist community, to whose religion meditation is a vital part of. Recent developments in scientific research have led to the interest of scientists in studying the benefits of meditation as part of psychedelic treatment modalities.

It is unclear how important psychedelics are in the meditation path for the Buddhist community. What is clear though, is that meditation and psychedelics are somehow entangled and work well together.

The scientific research of meditation in cognitive neuroscience has led to the creation of standard meditation styles accepted across different cultures. The renaissance in psychedelic research, on the other hand, has revealed a lot about the neurophysiology of states of consciousness caused by psychedelics like psilocybin and LSD.

There has undoubtedly been glaring evidence of an overlap between the neurophysiology of meditation and psychedelic states. Interestingly, little has been done to answer the question of how the two are intertwined.

Many meditative acts are focused on dissolving your sense of self and eliciting altered states of consciousness. Similarly, classical psychedelics like LSD work by disrupting the self-conscious state through a phenomenon known as Drug-Induced Ego Dissolution (“DIED”). In this way, psychedelics and meditation are similar. However, we’ll see below that the altered states in meditation can be used alongside psychedelics.

Meditation consists of over 100 cognitive training techniques, and researchers have found that the most common of these techniques is Focused Attention (“FA”). In this technique, you focus on a thought or an act, like your breathing, so keenly that your mind is clear and slowly begins to drift into a different cognitive state. This technique can be used as a ‘calm down’ step from a psychedelic trip.

Classic psychedelics (also known as hallucinogens) like psilocybin and LSD cause a Drug-Induced Ego Dissolution when taken in high dosage. Many people’s first experience with psychedelics is characterized by uncontrollable hallucinations and a steep downhill ‘calm down’. For a number of experienced users, however, DIED is a chance for them to meditate.

After a psychedelic peak, a general feeling of calmness and peace is reportedly felt by a sizeable number of users. In this state, right after the climax, your mind is sharper and in a position to see things in a different perspective. This is the best time to meditate, especially using focused attention.

Meditation, when done in the right spot, can help you control your psychedelic trip and improve your experience as a whole. Be sure to try it out at different points to see what works for you. Needless to say, lots of companies like ATAI Life Sciences AG will be sharing more information on this subject as it becomes available.

About PsychedelicNewsWire

PsychedelicNewsWire (PNW) is a specialized content distribution company that (1) aggregates and distributes news and information on the latest developments in all aspects and advances of psychedelics and their use, (2) creates PsychedelicNewsBreaks designed to quickly update investors on important industry news, (3) leverages a team of expert editors to enhance press releases for maximum impact, (4) assists companies with the management and optimization of social media across a range of platforms, and (5) delivers unparalleled corporate communication solutions. PNW stays abreast of the latest information and has established a reputation as the go to source for coverage of psychedelics, therapeutics and emerging market opportunities. Our team of seasoned journalists has a proven track record of helping both public and private companies gain traction with a wide audience of investors, consumers, media outlets and the general public by leveraging our expansive dissemination network of more than 5,000 key syndication outlets. PNW is committed to delivering improved visibility and brand recognition to companies operating in the emerging markets of psychedelics.

To receive instant SMS alerts, text “Groovy” to 888-902-4192 (U.S. Mobile Phones Only)

For more information please visit https://www.psychedelicnewswire.com

Please see full terms of use and disclaimers on the PsychedelicNewsWire website applicable to all content provided by PNW, wherever published or re-published: https://www.psychedelicnewswire.com/Disclaimer

Do you have questions or are you interested in working with PNW? Ask our Editor

PsychedelicNewsWire (PNW)
San Francisco, California
www.psychedelicnewswire.com
415.949.5050 Office
Editor@PsychedelicWire.com

PsychedelicNewsWire is part of the InvestorBrandNetwork.

Chris@PNW

Share
Published by
Chris@PNW

Recent Posts

NRx Pharmaceuticals Inc. (NASDAQ: NRXP) Pursues Dual Pathway for Preservative-Free Ketamine-Based Therapies

The company has refiled its Abbreviated New Drug Application (“ANDA”) for KETAFREE(TM), a preservative-free IV…

3 weeks ago

Global Psychedelic Week 2025 to Unite 5,000 People Across 100 Countries

The world’s first distributed psychedelic conference debuts with a global hybrid experience, 100+ speakers, 60+…

3 weeks ago

NRx Pharmaceuticals Inc. (NASDAQ: NRXP) Gains FDA Nod for Preservative-Free Ketamine Suitability Petition

FDA grants NRx Pharmaceuticals approval of a Suitability Petition for single-patient preservative-free ketamine. The decision…

4 weeks ago

NRx Pharmaceuticals Inc. (NASDAQ: NRXP) Secures FDA Fast Track for IV Ketamine Formulation NRX-100 in Suicidal Depression

The FDA designation expands the drug’s potential patient pool tenfold, to an estimated 13 million…

2 months ago

NRx Pharmaceuticals Inc. (NASDAQ: NRXP) Seeks FDA Ban on Toxic Ketamine Preservative

NRx Pharmaceuticals has filed a Citizen Petition with the FDA to remove benzethonium chloride from…

3 months ago

NRx Pharmaceuticals Inc. (NASDAQ: NRXP) Subsidiary to Acquire 49% Stake in Prominent Florida Neuropsychiatry Clinic

The acquisition of Cohen and Associates, a respected interventional psychiatry practice, by NRx subsidiary HOPE…

4 months ago